Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5246-5256

  Montero, Joan ^a,b,f   Morales, Albert ^a,b,f   Llacuna, Laura ^a,b,f   Lluis, Josep M ^a,b,f   Terrones, Oihana ^c   Basañez, Gorka ^c   Antonsson, Bruno ^d   Prieto, Jesús ^b,e   García Ruiz, Carmen ^a,b,f   Colell, Anna ^a,b,f   Fernández Checa, José C ^a,b,f,g  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c CSIC UPV Unidad de Biofisica UBF   (Spain)

^d MERCK SERONO S A   (Switzerland)

^e UNIVERSITY OF NAVARRA   (Spain)

^f INST D INVESTIGACIONS B   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CYTOCHROME C; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOSOME; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; STEROIDOGENIC ACUTE REGULATORY PROTEIN; UNCLASSIFIED DRUG; YM 53601; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOPROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; RAT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE SILENCING; GENETICS; LIVER MITOCHONDRION; LIVER TUMOR; MIDDLE AGED; NUDE MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CHOLESTEROL; DRUG RESISTANCE, NEOPLASM; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; GENE SILENCING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MITOCHONDRIA, LIVER; PHOSPHOPROTEINS; RATS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 48549093785     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6161     Document Type: Article

References (52)

1. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005;438:612-21.
2. Gimpl G, Burger K, Fahrenholz F. Cholesterol as modulator of receptor function. Biochemistry 1997;36:10959-74.
3. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002;110:597-603.
4. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31.
5. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:958-68.
6. Li YC, Park MJ, Ye S-K, Kim C-W, Kim Y-N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006;168:1107-18.
7. Siperstein MD. Cholesterol, cholesterogenesis and cancer. Adv Exp Med Biol 1995;369:155-66.
8. Duncan RE, El-Sohemy A, Archer MC. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 2004;279:33079-84.
9. Demierre MF, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
10. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2004;45:89-118.
11. Soccio RE, Breslow JL. Intracellular cholesterol transport. Arterioscler Thromb Vasc Biol 2004;24:1150-60.
12. Feo F, Canuto RA, Bertone G, Garcea R, Pani P. Cholesterol and phospholipid composition of mitochondria and microsomes isolated from morris hepatoma 5123 and rat liver. FEBS Lett 1973;33:229-32.
13. Crain RC, Clark RW, Harvey BE. Role of lipid transfer proteins in athe abnormal lipid content of Morris hepatoma mitochondria and microsomes. Cancer Res 1983;43:3197-202.
14. Campbell AM, Capuano A, Chan SHP. A cholesterol-binding and transporting protein from rat liver mitochondria. Biochim Biophys Acta 2002;1567:123-32.
15. Feo F, Canuto RA, Garcea R, Gabriel L. Effect of cholesterol content on some physical and functional properties of mitochondria isolated from adult rat liver, fetal liver, cholesterol-enriched liver and hepatomas AH-130, 3924A and 5123. Biochim Biophys Acta 1975;413:116-34.
16. Hall EA, Ren S, Hylemon PB, et al. Detection of the steroidogenic acute regulatory protein, StAR, in human liver cells. Biochim Biophys Acta 2005;1733:111-19.
17. Colell A, García-Ruiz C, Morales A, et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl- L-methionine. Hepatology 1997;26:699-708.
18. Coll O, Colell A, Garcia-Ruiz C, Kaplowitz N, Fernandez-Checa JC. Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology 2003;38:692-702.
19. Colell A, García-Ruiz C, Lluis JM, Coll O, Marí M, Fernández-Checa, JC. Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity. J Biol Chem 2003;278:33928-35.
20. Baggetto LG, Clottes E, Vial C. Low mitochondrial proton leak due to high membrane cholesterol content and cytosolic creatine kinase as two features of the deviant bioenergetics of Ehrlich and AS30-D tumor cells. Cancer Res 1992;52:4935-41.
21. Galluzzi L, Larochette N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006;5:4812-30.
22. Green DR. At the gates of death. Cancer Cell 2006;9:328-30.
23. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez M. Hepatocellular carcinoma. An overview. Ann Hepatol 2006;5:16-4.
24. Terrones O, Antonsson B, Yamaguchi H, et al. Lipidic pore formation by the concertad action of proapoptotic Bax and tBid. J Biol Chem 2004;279:30081-91.
25. Mari M, Colell A, Morales A. Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis. J Clin Invest 2004;113:895-904.
26. Duncan IW, Culbreth PH, Burtis CA. Determination of free, total, and esterified cholesterol by high-performance liquid chromatography. J Chromatogr 1979;162:281-92.
27. Mari M, Caballero F, Colell A, et al. Mitochondrial free loading sensitizes to TNF and Fas mediated steatohepatitis. Cell Metab 2006;4:185-98.
28. Van Blitterswijk WJ, van Hoeven RP, van der Meer B.W. Lipid structural order parameters (reciprocal of fluidity) in biomembranes derived from steady-state fluorescence polarization measurements. Biochim Biophys Acta 1981;644:323-32.
29. Hudd C, Euhus DM, LaRegina MC, Herbold DR, Palmer DC, Johnson FE. Effect of cholescytokinin on human cholangiocarcinoma xenografted into nude mice. Cancer Res 1985;45:1372-6.
30. LeBras M, Borgne-Sanchez A, Touat Z, et al. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 2006;66:9143-52.
31. Don AS, Kisker O, Dilda P, et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003;3:497-509.
32. Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol Ther 2005;4:14-22.
33. Kumar D, Kirshenbaum L, Li T, Danelisen I, Signal P. Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Ann N Y Acad Sci 1999;874:156-68.
34. Scharnagal H, Schinker R, Gierens H, Nauck M, Wieland H, März W. Effect of atorvastatin, simvastatin and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 2001;62:1545-55.
35. Hishita T, Tada-Oikawa S, Tohyama K, et al. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res 2001;61:2878-84.
36. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000;131:63-70.
37. Madesh M, Hajnoczky G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol 2001;155:1003-15.
38. Ichas F, Mazat JP. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta 1998;1366:33-50.
39. Rottem S, Cole RM, Habid WH, Barile MF, Hardegree MC. Structural characteristics of tetanolysin and its binding to lipid vesicles. J Bacteriol 1982;152:888-92.
40. Allende D, Simon SA, Mcintosh TJ. Melittin-induced bilayer leakage depends on lipid material properties: evidence for toroidal pores. Biophys J 2005;88:1828-37.
41. Forti S, Menestrina G. Staphylococcal α-toxin increases the permeability of lipid vesicles by cholesterol-and pH-dependent assembly of oligomeric channels. Eur J Biochem 1989;181:767-73.
42. Jones P, Kafonek S, Laurora I, Huninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-87.
43. Auerback BJ, Krause BR, Bisgaier CL, Newton RS. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atovastatin versus lovastatin. Atherosclerosis 1995;115:173-80.
44. Halestrap AP, Brenner C. The adenine nucleotide translocator: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem 2003;10:1507-25.
45. Kokoszka R, Waymire KG, Levy SE, et al. The ADP/ ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004;427:461-5.
46. Dolce V, Scarcia P, Iacopetta D, Palmieri F. A fourth ADP/ATP carrier isoform in man: identification, bacterial expression, functional characterization and tissue distribution. FEBS Lett 2005;579:633-7.
47. Palmieri F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pfluggers Arch 2004;447:689-709.
48. Bose M, Whittal RM, Miller L, Bose HS. Steroidogenic activity of StAR requires contact with mitochondrial VDAC1 and PCP. J Biol Chem 2008;14:8837-45.
49. Wang W, Yang L, Huang HW. Evidence of cholesterol accumulated in high curvature regions: implication to the curvature elastic energy for lipid mixtures. Biophys J 2007;92:2819-30.
50. Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2:941-48.
51. Brusselmans K, Timmermans L, Van de Sande T, et al. Squalene synthase: A determinant of raft-associated cholesterol and modulator of cancer cell proliferation. J Biol Chem 2007;282:18777-85.
52. Lucken-Ardjomande S, Montessuit S, Martinou JC. Bax activation and stress-induced apoptosis delayed by the accumulation of cholesterol in mitochondrial membranes. Cell Death Differ 2008;15:484-93.